Cargando…

An Index to Predict Ribavirin-Induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C

BACKGROUND: Single-nucleotide polymorphisms (SNP) in the inosine triphosphate pyrophosphatase (ITPA) gene correlate with ribavirin (RBV)-induced anemia in patients with chronic hepatitis C (CHC) receiving combination therapy. Managing anemia is an early priority in the treatment process. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Sheng-Hung, Peng, Cheng-Yuan, Lai, Hsueh-Chou, Su, Wen-Pang, Lin, Chia-Hsin, Li, Yu-Fen, Chuang, Po-Heng, Chen, Ching-Hsiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377223/ https://www.ncbi.nlm.nih.gov/pubmed/25834588 http://dx.doi.org/10.5812/hepatmon.27148

Ejemplares similares

New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis
por: Wang, Hung-Wei, et al.
Publicado: (2017)

Publisher Correction: New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis
por: Wang, Hung-Wei, et al.
Publicado: (2018)

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B
por: Peng, Cheng-Yuan, et al.
Publicado: (2017)

Rapid decline of noninvasive fibrosis index values in patients with hepatitis C receiving treatment with direct-acting antiviral agents
por: Hsu, Wei-Fan, et al.
Publicado: (2019)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
por: Hung, Hsuan-Yu, et al.
Publicado: (2021)

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
por: Hsieh, Ming-Han, et al.
Publicado: (2022)

Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C
por: Chen, Sheng-Hung, et al.
Publicado: (2015)

Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir
por: Chen, Chien-Hung, et al.
Publicado: (2017)

Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C
por: Chen, Sheng-Hung, et al.
Publicado: (2012)

Modeling Ribavirin‐Induced Anemia in Patients with Chronic Hepatitis C Virus
por: Wu, LS, et al.
Publicado: (2016)

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
por: Liu, Chen-Hua, et al.
Publicado: (2020)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C
por: Chen, Sheng-Hung, et al.
Publicado: (2018)

Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy
por: Krishnan, Sheeja M., et al.
Publicado: (2011)

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection
por: Rosenthal, Philip, et al.
Publicado: (2019)

On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2020)

Phenotypes and Genotypes of Patients with Pantothenate Kinase-Associated Neurodegeneration in Asian and Caucasian Populations: 2 Cases and Literature Review
por: Lee, Chih-Hong, et al.
Publicado: (2013)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C
por: Chen, Sheng-Hung, et al.
Publicado: (2016)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Risk factors for ribavirin treatment failure in Asian organ transplant recipients with chronic hepatitis E infection
por: Low, En Xian Sarah, et al.
Publicado: (2019)

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort
por: Yen, Yi-Hao, et al.
Publicado: (2018)

Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
por: Liu, Chen-Hua, et al.
Publicado: (2018)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
por: Liu, Chen-Hua, et al.
Publicado: (2021)

Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-Analysis
por: Wang, Xiwei, et al.
Publicado: (2014)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
por: Sato, Shinya, et al.
Publicado: (2019)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Combined Liver Stiffness and Α-fetoprotein Further beyond the Sustained Virologic Response Visit as Predictors of Long-Term Liver-Related Events in Patients with Chronic Hepatitis C
por: Chen, Sheng-Hung, et al.
Publicado: (2022)

Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
por: Liu, Chen-Hua, et al.
Publicado: (2015)

Optimal Erythrocyte Ribavirin Level to Reduce the Risk of Anemia and Obtain an Early Virological Response in Patients with Chronic Hepatitis C Caused by Genotype 1b Infection
por: Kubota, Rie, et al.
Publicado: (2010)

Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin
por: Wu, Chia-Min, et al.
Publicado: (2021)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients
por: Lee, Chuan-Mo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sb9fo0e3kv2bopqrd40u6pnnrj